Pharma — India Copyright Cases
6 decisions indexed
Page 1 of 1 · 6 total
Jamp India Pharmaceuticals Private Limited v.Jubilant Generics Ltd.
This appeal before the Allahabad High Court addressed challenges to a Commercial Court's injunction order. The plaintiff, Jamp India Pharmaceuticals Private Limited, successfully argued that its comprehensive Product Dossiers—containing sensitive technical data for generic drugs like Losartan and Amlodipine—qualify as protected literary works under the Copyright Act, 1957. The court found that the defendants misappropriated these confidential dossiers by transferring them from a Canadian subsidiary to their Indian affiliate, leading to unauthorized manufacturing and use in India. Consequently, the appeals were dismissed, upholding the injunction.
Curewin Pharmaceuticals Pvt. Ltd. v.Curewin Hylico Pharma Pvt. Ltd.
This case involves disputes between two pharmaceutical companies regarding the artistic work and copyright protection of 'ENERZY' powder. The core legal challenge revolved around whether the plaintiff's suit, which sought injunctions against infringement, should be rejected under Order 7 Rule 11 CPC because its valuation was tied to a prior agreement. The High Court examined the distinction between statutory rights (Copyright Act) and contractual obligations, ultimately modifying the trial court's order to allow the suit to proceed without mandating the inclusion of all specific pleadings from the external agreement.
Curewin Pharmaceuticals Pvt. Ltd. v.Curewin Hylico Pharma Pvt. Ltd.
This case involves a dispute over the artistic work 'ENERZY powder' between Curewin Pharmaceuticals Pvt. Ltd. and Curewin Hylico Pharma Pvt. Ltd. The core legal battle centered on whether the Commercial Court was correct in directing the plaintiff to amend their plaint based on an agreement dated 22.01.2015, specifically regarding valuation for court fees. The High Court examined the matter under Article 227 of the Constitution and ultimately ruled that the statutory copyright right should govern the suit's substance, not solely the contractual terms.
Paras Ayurvedic Pharma Pvt.Ltd v.Salman Iqbal Ahmed Momin And Anr
Paras Ayurvedic Pharma Pvt.Ltd appealed against two lower court orders concerning a commercial IP suit alleging copyright infringement and passing off related to 'Roghan Sukoon Massage Oil'. The core dispute centered on whether the defendant's product copied the plaintiff's unique artistic work and brand elements, and whether the plaintiffs had sufficient knowledge of the alleged infringement. The Bombay High Court dismissed the appeal, upholding the lower court's decision that the plaintiffs were entitled to relief.
SaNOtize Research and Development Corp. v.Lupin Ltd
SaNOtize Research and Development Corp. filed suit against Lupin Limited alleging infringement of its Nitric Oxide Releasing Solution (NORS) technology, breach of confidentiality, and copyright infringement related to its nasal spray product, NONS/ENOVID. The dispute centers on the use of a proprietary dual-chamber delivery system for nitric oxide in medical treatment. The court granted an interim prohibitory injunction against Lupin's Indian arm and manufacturer.
Dabur India Ltd. v.Sh. Ashok Aushadhi Udyog
Dabur India Ltd. filed a suit against Sh. Ashok Aushadhi Udyog alleging that the latter had adopted deceptively similar labels for ayurvedic tonics, specifically Dashmularishta and Ashokarishta. Dabur claimed ownership of copyright in the artistic work comprising these distinctive product labels. The court found sufficient evidence to establish Dabur's proprietary rights and ruled that the defendant's use constituted infringement. Consequently, the suit was decreed with permanent injunctions and punitive damages awarded.
Copyright infringement or licensing dispute?
From digital piracy to content licensing, Arctic's copyright practice covers enforcement, licensing structuring, and fair-use defences.